You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDexamethasone
Accession NumberDB01234  (APRD00674)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
Description

An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]

Structure
Thumb
Synonyms
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16α-Methyl-9α-fluoro-1-dehydrocortisol
9alpha-Fluoro-16alpha-methylprednisolone
9α-Fluoro-16α-methylprednisolone
Decadron
Dexametasona
Dexamethasone
Dexamethasonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accufix II Dec Model 033-212implant.7 mgnil; refer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Decadron Phosphate Eye Ear Sol 0.1%liquid1 mgophthalmic; oticMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1960-12-311998-04-21Canada
Decadron Phosphate Inj 4mg/mlliquid4 mgintramuscular; intravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-312001-08-01Canada
Decadron Tab 0.5mgtablet.5 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1958-12-312002-07-29Canada
Decadron Tab 4mgtablet4 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1976-12-312003-08-08Canada
Dexamethasone Omega Unidosesolution10 mgintramuscular; intrasynovial; intravenousOmega Laboratories Ltd2013-05-08Not applicableCanada
Dexamethasone Sod Phos Inj 4mg/mlliquid4 mgintramuscular; intravenousTaro Pharmaceuticals Inc1989-12-312001-08-21Canada
Dexamethasone Sod Phosph Inj 10mg/ml USPliquid10 mgintramuscular; intrasynovial; intravenousSandoz Canada Incorporated1990-12-31Not applicableCanada
Dexamethasone Sodium Phosphate 0.1%drops.1 %ophthalmic; oticRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Dexamethasone Sodium Phosphate Inj USP 4mg/mlsolution4 mgintramuscular; intrasynovial; intravenousSandoz Canada Incorporated1986-12-31Not applicableCanada
Dexamethasone Sodium Phosphate Injection Sdzsolution4 mgintramuscular; intrasynovial; intravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Dexamethasone Sodium Phosphate Injection Sdzsolution10 mgintramuscular; intrasynovial; intravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Dexamethasone Sodium Phosphate Injection, USPliquid4 mgintra-articular; intramuscular; intravenousSterimax Inc1992-12-31Not applicableCanada
Dexamethasone Sodium Phosphate Injection, USPsolution10 mgintramuscular; intravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Dexamethasone Sodium Phosphate Injection, USPsolution4 mgintra-articular; intralesional; intramuscular; intravenous; soft tissue injectionMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Dexamethasone-omegaliquid10 mgintramuscular; intravenousOmega Laboratories Ltd1999-06-30Not applicableCanada
Dexamethasone-omegaliquid4 mgintra-articular; intralesional; intramuscular; intravenous; soft tissue injectionOmega Laboratories Ltd1999-04-01Not applicableCanada
Dexasone 0.5mgtablet0.5 mgoralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
Dexasone 0.75mgtablet0.75 mgoralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
Dexasone 4mgtablet4 mgoralValeant Canada Lp Valeant Canada S.E.C.1979-12-31Not applicableCanada
Diodex Solution 0.1%solution0.1 %ophthalmic; oticDioptic Pharmaceuticals Inc1994-12-31Not applicableCanada
Dom-dexamethasone Tablet 4mgtablet4 mgoralDominion Pharmacal1999-03-04Not applicableCanada
Encor Dec Model 033-159 Imp 0.5mg/impimplant.5 mgrefer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Encor Dec Model 033-443 Imp 0.5mg/impimplant.5 mgrefer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Encor Dec Model 033-448 Imp 0.5mg/impimplant.5 mgrefer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Encor Dec Model 033-757 Imp 0.5mg/impimplant0.5 mgrefer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311996-09-10Canada
Encor Dec Model 033-856 Imp 0.5mg/impimplant.5 mgrefer (see dosage form)Telectronics Pacing Systems Inc.1994-12-311996-09-10Canada
Hexadrol Phosphate Inj 10mg/mlliquid10 mgintramuscular; intravenousOrganon Teknika Canada Inc.1987-12-312001-09-18Canada
Hexadrol Phosphate Inj 4mg/mlliquid4 mgintramuscular; intravenousOrganon Teknika Canada Inc.1987-12-312001-09-18Canada
Maxidexsuspension1 mg/mLophthalmicAlcon Laboratories, Inc.1966-05-15Not applicableUs
Maxidex Ont 0.1%ointment0.1 %ophthalmicAlcon Canada Inc1966-12-31Not applicableCanada
Maxidex Sus 0.1%drops0.1 %ophthalmicAlcon Canada Inc1977-12-31Not applicableCanada
Ocudex Liq 0.1%liquid.1 %ophthalmic; topicalHerdt Et Charton Inc.1994-12-311999-09-17Canada
Odan-dexamethasonesolution0.1 %ophthalmic; oticOdan Laboratories Ltd1985-12-31Not applicableCanada
Ozurdeximplant.7 mg/1intravitrealAllergan, Inc.2009-09-01Not applicableUs
Ozurdeximplant0.7 mgintravitrealAllergan Inc2011-06-02Not applicableCanada
PHL-dexamethasonetablet0.75 mgoralPharmel Inc1998-02-17Not applicableCanada
PHL-dexamethasonetablet0.5 mgoralPharmel Inc1998-02-17Not applicableCanada
PHL-dexamethasoneliquid10 mgintramuscular; intravenousPharmel Inc2004-12-06Not applicableCanada
PHL-dexamethasoneelixir0.5 mgoralPharmel Inc2004-12-06Not applicableCanada
PHL-dexamethasonetablet4 mgoralPharmel Inc1998-02-17Not applicableCanada
PMS Dexamethasone Elixir 0.5mg/5mlliquid0.5 mgoralPharmascience Inc1992-12-31Not applicableCanada
PMS Dexamethasone Tab 0.5mg USPtablet0.5 mgoralPharmascience Inc1996-08-26Not applicableCanada
PMS Dexamethasone Tab 0.75mg USPtablet0.75 mgoralPharmascience Inc1996-09-05Not applicableCanada
PMS Dexamethasone Tab 4mgtablet4 mgoralPharmascience Inc1996-09-05Not applicableCanada
PMS-dexamethasonetablet2 mgoralPharmascience Inc2006-06-08Not applicableCanada
PMS-dexamethasone Sod Phosphate Dps 1mg/mldrops1 mgophthalmic; oticPharmascience Inc1989-12-31Not applicableCanada
PMS-dexamethasone Sod Phosphate Inj 10mg/mlliquid10 mgintramuscular; intravenousPharmascience Inc1990-12-31Not applicableCanada
PMS-dexamethasone Sod Phosphate Inj 4mg/mlsolution4 mgintra-articular; intramuscular; intravenousPharmascience Inc1989-12-31Not applicableCanada
Pro-dexamethasone - 4tablet4 mgoralPro Doc Limitee2008-07-04Not applicableCanada
R.O.-dexsonedrops.1 %ophthalmic; oticRichmond Pharmaceuticals Inc.1992-12-311997-08-11Canada
Ratio-dexamethasonetablet4 mgoralTeva Canada Limited1999-10-29Not applicableCanada
Ratio-dexamethasonetablet0.5 mgoralTeva Canada Limited1999-10-29Not applicableCanada
Ratio-dexamethasone Tablets, USPtablet0.75 mgoralRatiopharm Inc Division Of Teva Canada Limited1999-10-292009-07-17Canada
Sandoz Dexamethasonedrops1 mgophthalmic; oticSandoz Canada Incorporated1990-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dexamethasonetablet0.5 mgoralApotex Inc2004-11-17Not applicableCanada
Apo-dexamethasonetablet4 mgoralApotex Inc2004-03-08Not applicableCanada
Baycadronelixir.5 mg/5mLoralWockhardt USA, LLC1983-07-27Not applicableUs
Dexamethasonetablet4 mg/1oralH.J. Harkins Company, Inc.1983-04-28Not applicableUs
Dexamethasonetablet4 mg/1oralPd Rx Pharmaceuticals, Inc.1978-07-19Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1983-04-28Not applicableUs
Dexamethasonetablet4 mg/1oralCardinal Health2011-06-29Not applicableUs
Dexamethasonetablet1.5 mg/1oralECR Pharmaceuticals2006-09-01Not applicableUs
Dexamethasonetablet.75 mg/1oralPar Pharmaceutical Inc.1983-04-28Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralSTI Pharma LLC1976-09-21Not applicableUs
Dexamethasonetablet.75 mg/1oralPd Rx Pharmaceuticals, Inc.1975-06-03Not applicableUs
Dexamethasonetablet4 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
Dexamethasonetablet4 mg/1oralPhysicians Total Care, Inc1994-01-19Not applicableUs
Dexamethasonetablet.75 mg/1oralA S Medication Solutions Llc1975-06-03Not applicableUs
Dexamethasonetablet6 mg/1oralRoxane Laboratories, Inc1983-09-15Not applicableUs
Dexamethasonetablet.5 mg/1oralPar Pharmaceutical Inc.1983-04-28Not applicableUs
Dexamethasonetablet2 mg/1oralRebel Distributors Corp1982-08-26Not applicableUs
Dexamethasonetablet1.5 mg/1oralBlenheim Pharmacal, Inc.2013-12-10Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1978-07-19Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralCardinal Health1983-07-27Not applicableUs
Dexamethasonetablet1.5 mg/1oralECR Pharmaceuticals2009-04-01Not applicableUs
Dexamethasonetablet4 mg/1oralDispensing Solutions, Inc.1978-07-19Not applicableUs
Dexamethasonetablet6 mg/1oralPhysicians Total Care, Inc2008-05-30Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1978-07-19Not applicableUs
Dexamethasonetablet6 mg/1oralRoxane Laboratories, Inc1983-09-15Not applicableUs
Dexamethasonetablet4 mg/1oralRoxane Laboratories, Inc1978-07-19Not applicableUs
Dexamethasonetablet1 mg/1oralRebel Distributors Corp1983-09-15Not applicableUs
Dexamethasonetablet.75 mg/1oralH.J. Harkins Company, Inc.1983-04-28Not applicableUs
Dexamethasonetablet1.5 mg/1oralPhysicians Total Care, Inc.2005-06-13Not applicableUs
Dexamethasonetablet1.5 mg/1oralRoxane Laboratories, Inc2006-07-07Not applicableUs
Dexamethasonetablet2 mg/1oralRoxane Laboratories, Inc1982-08-26Not applicableUs
Dexamethasonetablet4 mg/1oralRebel Distributors Corp1978-07-19Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralQualitest Pharmaceuticals2011-05-11Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1978-07-19Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralRising Pharmaceuticals, Inc.2011-08-01Not applicableUs
Dexamethasonetablet4 mg/1oralProficient Rx LP1978-07-19Not applicableUs
Dexamethasonetablet2 mg/1oralPhysicians Total Care, Inc2005-06-21Not applicableUs
Dexamethasonetablet.75 mg/1oralRoxane Laboratories, Inc1975-06-03Not applicableUs
Dexamethasonetablet1.5 mg/1oralRoxane Laboratories, Inc2006-07-07Not applicableUs
Dexamethasonetablet2 mg/1oralPd Rx Pharmaceuticals, Inc.1982-08-26Not applicableUs
Dexamethasonetablet.75 mg/1oralRebel Distributors Corp1975-06-03Not applicableUs
Dexamethasonetablet.75 mg/1oralA S Medication Solutions Llc1983-04-28Not applicableUs
Dexamethasonetablet.5 mg/1oralRoxane Laboratories, Inc1975-07-25Not applicableUs
Dexamethasonetablet1 mg/1oralRoxane Laboratories, Inc1983-09-15Not applicableUs
Dexamethasonetablet4 mg/1oralSTAT Rx USA LLC1978-07-19Not applicableUs
Dexamethasonetablet4 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1978-07-19Not applicableUs
Dexamethasonetablet.75 mg/1oralbryant ranch prepack1975-06-03Not applicableUs
Dexamethasonetablet1.5 mg/1oralPhysicians Total Care, Inc1996-06-21Not applicableUs
Dexamethasonetablet2 mg/1oralRoxane Laboratories, Inc1982-08-26Not applicableUs
Dexamethasonetablet.75 mg/1oralRoxane Laboratories, Inc1975-06-03Not applicableUs
Dexamethasonetablet4 mg/1oralAidarex Pharmaceuticals LLC1983-04-28Not applicableUs
Dexamethasonetablet6 mg/1oralPar Pharmaceutical Inc.1983-11-28Not applicableUs
Dexamethasonetablet1.5 mg/1oralbryant ranch prepack2006-07-07Not applicableUs
Dexamethasonetablet4 mg/1oralRoxane Laboratories, Inc1978-07-19Not applicableUs
Dexamethasonetablet.5 mg/1oralRoxane Laboratories, Inc1975-07-25Not applicableUs
Dexamethasonetablet1.5 mg/1oralECR Pharmaceuticals2009-04-01Not applicableUs
Dexamethasonetablet4 mg/1oralPar Pharmaceutical Inc.1983-04-28Not applicableUs
Dexamethasonetablet4 mg/1oralbryant ranch prepack1978-07-19Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralMorton Grove Pharmaceuticals, Inc.1983-07-27Not applicableUs
Dexamethasoneelixir.5 mg/5mLoralSTI Pharma LLC1976-09-21Not applicableUs
Dexamethasonetablet.5 mg/1oralPhysicians Total Care, Inc2009-01-28Not applicableUs
Dexamethasonetablet2 mg/1oralA S Medication Solutions Llc1982-08-26Not applicableUs
Dexamethasonetablet4 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1983-04-28Not applicableUs
Dexamethasonetablet2 mg/1oralCardinal Health2011-06-29Not applicableUs
Dexamethasonetablet1.5 mg/1oralECR Pharmaceuticals2000-04-01Not applicableUs
Dexamethasonetablet1.5 mg/1oralPar Pharmaceutical Inc.1983-04-28Not applicableUs
Dexamethasonetablet.75 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
Dexamethasonetablet.75 mg/1oralPhysicians Total Care, Inc1996-05-10Not applicableUs
Dexamethasonetablet4 mg/1oralA S Medication Solutions Llc1978-07-19Not applicableUs
Dexamethasonetablet1 mg/1oralRoxane Laboratories, Inc1983-09-15Not applicableUs
Dexamethasonesolution.5 mg/5mLoralRoxane Laboratories, Inc2007-11-01Not applicableUs
Dexamethasone Intensolsolution, concentrate1 mg/mLoralRoxane Laboratories, Inc1983-09-01Not applicableUs
Dexamethasone Intensolsolution, concentrate1 mg/mLoralCarilion Materials Management1983-09-01Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicMajor Pharmaceuticals1996-07-26Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2003-05-29Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection10 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.2010-01-15Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection10 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1982-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2000-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection10 mg/mLintramuscular; intravenousGENERAL INJECTABLES AND VACCINES, INC.2014-05-26Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintravenousREMEDYREPACK INC.2013-08-13Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscular; intravenousCardinal Health2000-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueGeneral Injectables and Vaccines, Inc2016-02-18Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueA S Medication Solutions Llc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscularREMEDYREPACK INC.2013-11-18Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousCardinal Health2003-05-29Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueCardinal Health2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscular; intravenousA S Medication Solutions Llc2000-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intramuscular; intravenousGeneral Injectables and Vaccines, Inc2015-08-21Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscular; intravenousCardinal Health2000-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAmerican Regent, Inc.1990-09-30Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueCardinal Health2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphatesolution1 mg/mLophthalmicPhysicians Total Care, Inc.2005-06-20Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintramuscular; intravenousA S Medication Solutions Llc2000-09-07Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicRebel Distributors Corp1996-07-26Not applicableUs
Dexamethasone Sodium Phosphateinjection4 mg/5mLintra-articular; intralesional; intramuscular; intravenousGeneral Injectables & Vaccines, Inc.2011-07-18Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueCardinal Health2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAmerican Regent, Inc.1990-09-30Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAuro Medics Pharma Llc2015-12-01Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articularREMEDYREPACK INC.2015-07-17Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicA S Medication Solutions Llc1996-07-26Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicStat Rx USA1996-07-26Not applicableUs
Dexamethasone Sodium Phosphateinjection10 mg/mLintramuscularREMEDYREPACK INC.2013-08-13Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAmerican Regent, Inc.1990-09-30Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAuro Medics Pharma Llc2015-12-01Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphatesolution1 mg/mLophthalmicSandoz Inc2004-07-01Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueBD Rx Inc.2015-10-30Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicBausch & Lomb Incorporated1996-07-26Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicButler Animal Health Supply1996-07-26Not applicableUs
Dexamethasone Sodium Phosphateinjection10 mg/mLintramuscular; intravenousCardinal Health1982-09-07Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueAuro Medics Pharma Llc2015-12-01Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphatesolution1 mg/mLophthalmicRebel Distributors Corp1985-01-16Not applicableUs
Dexamethasone Sodium Phosphatesolution1 mg/mLophthalmicDispensing Solutions, Inc.2004-07-01Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissuePfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2005-04-05Not applicableUs
Dexamethasone Sodium Phosphatesolution/ drops1 mg/mLophthalmicPhoenix Pharmaceutical, Inc.1996-07-26Not applicableUs
Dexamethasone Sodium Phosphateinjection, solution10 mg/mLintramuscular; intravenousMylan Institutional LLC2011-05-11Not applicableUs
Dexamethasone Sodium Phosphatesinjection, solution4 mg/mLintra-articular; intralesional; intramuscular; intravenous; soft tissueCardinal Health1990-09-30Not applicableUs
Dexamethsonetablet4 mg/1oralNorthwind Pharmaceuticals, LLC2014-08-11Not applicableUs
Direct Rxtablet1.5 mg/1oralDIRECT RX2015-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DecadronSidus
Brand mixtures
NameLabellerIngredients
999 Itch ReliefChina Resources Sanjiu Medical & Pharmaceutical Co Ltd
CiprodexRebel Distributors Corp
Dioptrol OintmentDioptic Pharmaceuticals Inc
Dioptrol SuspensionDioptic Pharmaceuticals Inc
MaxitrolAlcon Laboratories, Inc.
Maxitrol OntAlcon Canada Inc
MethedexMajor Pharmaceuticals
Neo-poly-dexButler Animal Health Supply
Neodecadron Eye Ear Soln 0.1%Merck Frosst Canada & Cie, Merck Frosst Canada & Co.
Neomycin and Polymyxin B Sulfates and DexamethasonePaddock Laboratories, LLC
Neomycin Polymyxin B Sulfates and DexamethasoneMwi/Vet One
Neomycin Sulfate, Polymyxin B Sulfate and DexamethasoneSTAT RX LLC USA
NpdPhoenix Pharmaceutical, Inc.
Odan-trolOdan Laboratories Ltd
Sandoz OpticortSandoz Canada Incorporated
Sofracort Ear/eye OintmentRoussel Canada Inc.
Sofracort Sterile Ear/eye DropsSanofi Aventis Canada Inc
Sofracort Sterile Ear/eye OintmentHoechst Roussel Canada Inc.
TobradexAlcon Laboratories, Inc.
Tobradex Oph OintmentAlcon Canada Inc
Tobradex Oph SusAlcon Canada Inc
Tobradex STAlcon Laboratories, Inc.
Tobramycin and DexamethasoneRebel Distributors Corp
Salts
Name/CASStructureProperties
Dexamethasone acetate
Thumb
  • InChI Key: AKUJBENLRBOFTD-RPRRAYFGSA-N
  • Monoisotopic Mass: 434.210466929
  • Average Mass: 434.4977
DBSALT000383
Dexamethasone phosphate
ThumbNot applicableDBSALT001216
Dexamethasone sodium phosphate
Thumb
  • InChI Key: PLCQGRYPOISRTQ-FCJDYXGNSA-L
  • Monoisotopic Mass: 516.130121939
  • Average Mass: 516.4046
DBSALT000843
Categories
UNII7S5I7G3JQL
CAS number50-02-2
WeightAverage: 392.4611
Monoisotopic: 392.199902243
Chemical FormulaC22H29FO5
InChI KeyInChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationInjection: for the treatment of endocrine disorders, rheumatic D=disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.
Ophthalmic ointment and solution: for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Ophthalmic solution only: for the treatment of steroid responsive inflammatory conditions of the external auditory meatus
Topic cream: for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Oral aerosol: for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
PharmacodynamicsDexamethasone and its derivatives, dexamethasone sodium phosphate and dexamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions.
Mechanism of actionDexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements (glucocorticoid response elements) which results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Related Articles
Absorption80-90%
Volume of distributionNot Available
Protein binding70%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Dexamethasone
6-beta-hydroxydexamethasoneDetails
Route of eliminationNot Available
Half life36-54 hours
ClearanceNot Available
ToxicityOral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9781
Caco-2 permeable+0.8304
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8112
P-glycoprotein inhibitor IINon-inhibitor0.8134
Renal organic cation transporterNon-inhibitor0.7971
CYP450 2C9 substrateNon-substrate0.8733
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7315
CYP450 1A2 substrateNon-inhibitor0.938
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9247
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9169
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9399
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1482 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9558
hERG inhibition (predictor II)Inhibitor0.5091
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Implantnil; refer (see dosage form).7 mg
Suspensionauricular (otic)
Suspensionotic
Suspension/ dropsauricular (otic)
Liquidophthalmic; otic1 mg
Tabletoral.5 mg
Elixiroral.5 mg/5mL
Solutionoral.5 mg/5mL
Tabletoral.5 mg/1
Tabletoral.75 mg/1
Tabletoral1 mg/1
Tabletoral1.5 mg/1
Tabletoral2 mg/1
Tabletoral4 mg/1
Tabletoral6 mg/1
Solution, concentrateoral1 mg/mL
Solutionintramuscular; intrasynovial; intravenous10 mg
Liquidintramuscular; intrasynovial; intravenous10 mg
Injectionintra-articular; intralesional; intramuscular; intravenous4 mg/5mL
Injectionintramuscular10 mg/mL
Injectionintramuscular; intravenous10 mg/mL
Injection, solutionintra-articular4 mg/mL
Injection, solutionintra-articular; intralesional; intramuscular; intravenous; soft tissue4 mg/mL
Injection, solutionintra-articular; intramuscular; intravenous4 mg/mL
Injection, solutionintramuscular4 mg/mL
Injection, solutionintramuscular; intravenous10 mg/mL
Injection, solutionintramuscular; intravenous4 mg/mL
Injection, solutionintravenous4 mg/mL
Solutionophthalmic1 mg/mL
Solution/ dropsophthalmic1 mg/mL
Solutionintramuscular; intrasynovial; intravenous4 mg
Liquidintra-articular; intramuscular; intravenous4 mg
Solutionintra-articular; intralesional; intramuscular; intravenous; soft tissue injection4 mg
Solutionintramuscular; intravenous10 mg
Liquidintra-articular; intralesional; intramuscular; intravenous; soft tissue injection4 mg
Solutionophthalmic; otic0.1 %
Ointmentophthalmic; topical
Implantrefer (see dosage form).5 mg
Implantrefer (see dosage form)0.5 mg
Liquidintramuscular; intravenous4 mg
Suspensionophthalmic1 mg/mL
Ointmentophthalmic0.1 %
Dropsophthalmic0.1 %
Ointmentophthalmic
Suspensionophthalmic
Solution/ dropsophthalmic
Liquidophthalmic; otic
Liquidophthalmic; topical.1 %
Implantintravitreal.7 mg/1
Implantintravitreal0.7 mg
Elixiroral0.5 mg
Liquidoral0.5 mg
Tabletoral0.5 mg
Tabletoral0.75 mg
Tabletoral4 mg
Tabletoral2 mg
Liquidintramuscular; intravenous10 mg
Solutionintra-articular; intramuscular; intravenous4 mg
Dropsophthalmic; otic.1 %
Dropsophthalmic; otic1 mg
Solutionophthalmic; otic
Ointmentophthalmic; otic
Dropsophthalmic; otic
Dropstopical
Ointmenttopical
Suspension/ dropsophthalmic
Prices
Unit descriptionCostUnit
Ozurdex 0.7 mg implant1554.0USD implant
Maxidex 0.1% Suspension 15ml Bottle97.96USD bottle
Maxitrol 0.1-5-10000 Ointment 3.5 gm Tube87.3USD tube
Maxitrol 5-10000-0.1 Suspension 5ml Bottle75.88USD bottle
Maxidex 0.1% Suspension 5ml Bottle53.57USD bottle
Dexamethasone Sodium Phosphate 4 mg/ml Solution (1 Box = 25x1ml Vials)41.99USD box
Dexamethasone micronized powd41.31USD g
Dexamethasone powder21.27USD g
Dexamethasone Sodium Phosphate 0.1% Solution 5ml Bottle19.99USD bottle
Dexamethasone acetate powd15.12USD g
Dexamethasone sod ph powder14.24USD g
Dexamethasone Sodium Phosphate 4 mg/ml Solution 5ml Vial13.99USD vial
Dexamethasone Sodium Phosphate 10 mg/ml4.78USD ml
Dexamethasone Sodium Phosphate 4 mg/ml 1 Vial = 5ml4.0USD ml
Dexamethasone 0.1% eye drop3.43USD ml
Dexasol 0.1% eye drops3.38USD ml
Maxidex 0.1 % Ointment2.69USD g
Dexamethasone 10 mg/ml vial2.56USD ml
Maxidex 0.1% eye drops2.36USD ml
Dexamethasone Sodium Phosphate 4 mg/ml1.77USD ml
Maxidex 0.1 % Suspension1.73USD ml
Sandoz Dexamethasone Sod. Phosphate 0.1 % Solution1.38USD ml
Pms-Dexamethasone Sodium Phosp 10 mg/ml1.34USD ml
Dexamethasone 4 mg/ml vial1.04USD ml
Dexamethasone 6 mg tablet1.01USD tablet
Dexasone 4 mg Tablet0.86USD tablet
Apo-Dexamethasone 4 mg Tablet0.8USD tablet
Pms-Dexamethasone 4 mg Tablet0.8USD tablet
Ratio-Dexamethasone 4 mg Tablet0.8USD tablet
Dexamethasone 2 mg tablet0.68USD tablet
Dexamethasone 1 mg/1 ml soln0.65USD ml
Dexamethasone 4 mg tablet0.6USD tablet
Dexamethasone 1 mg tablet0.49USD tablet
Pms-Dexamethasone 0.75 mg Tablet0.47USD tablet
Pms-Dexamethasone 2 mg Tablet0.43USD tablet
Dexamethasone 0.5 mg/5ml Elixir0.4USD ml
Dexamethasone 0.75 mg tablet0.38USD tablet
Dexamethasone 1.5 mg tablet0.35USD tablet
Dexamethasone 0.5 mg tablet0.31USD tablet
Apo-Dexamethasone 0.5 mg Tablet0.21USD tablet
Pms-Dexamethasone 0.5 mg Tablet0.2USD tablet
Ratio-Dexamethasone 0.5 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6284804 No2000-08-102020-08-10Us
US6359016 No2000-08-102020-08-10Us
US6726918 No2000-10-202020-10-20Us
US6899717 No2003-11-012023-11-01Us
US7033605 No2000-10-202020-10-20Us
US7767223 No2001-11-282021-11-28Us
US7795316 No2008-08-032028-08-03Us
US8034366 No2003-01-092023-01-09Us
US8034370 No2003-01-092023-01-09Us
US8043628 No2000-10-202020-10-20Us
US8063031 No2000-10-202020-10-20Us
US8088407 No2000-10-202020-10-20Us
US8101582 No2007-12-192027-12-19Us
US8450287 No2007-12-192027-12-19Us
US8506987 No2003-01-092023-01-09Us
US8846650 No2005-06-042025-06-04Us
US9012437 No2000-10-202020-10-20Us
US9149486 No2002-09-132022-09-13Us
US9192511 No2003-01-092023-01-09Us
US9283178 No2000-10-202020-10-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point170-229Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation. Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.
water solubility89 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.83HANSCH,C ET AL. (1995)
logS-3.64ADME Research, USCD
Caco2 permeability-4.75ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0505 mg/mLALOGPS
logP1.93ALOGPS
logP1.68ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.49 m3·mol-1ChemAxon
Polarizability40.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
References
Synthesis Reference

Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation.
Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.

General ReferencesNot Available
External Links
ATC CodesA01AC02C05AA09D07AB19D07CB04D07XB05D10AA03H02AB02R01AD03R01AD53S01BA01S01CA01S01CB01S02BA06S02CA06S03BA01S03CA01
AHFS Codes
  • 52:08.08
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (96 KB)
MSDSDownload (74.8 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dexamethasone.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dexamethasone.
AldesleukinDexamethasone may decrease the antineoplastic activities of Aldesleukin.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dexamethasone.
Aluminum hydroxideThe bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.
Amphotericin BDexamethasone may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Dexamethasone can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Dexamethasone.
AsparaginaseThe serum concentration of Dexamethasone can be increased when it is combined with Asparaginase.
Asparaginase Erwinia chrysanthemiThe serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Erwinia chrysanthemi.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Dexamethasone.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Dexamethasone.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Dexamethasone.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Dexamethasone.
BexaroteneThe serum concentration of Dexamethasone can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Dexamethasone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Dexamethasone.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Dexamethasone.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone.
Calcium carbonateThe bioavailability of Dexamethasone can be decreased when combined with Calcium carbonate.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dexamethasone.
CapromabDexamethasone may decrease effectiveness of Capromab as a diagnostic agent.
CarbamazepineThe serum concentration of Dexamethasone can be decreased when it is combined with Carbamazepine.
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Dexamethasone.
ChlorotrianiseneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorotrianisene.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dexamethasone.
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Dexamethasone.
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Dexamethasone.
ColesevelamColesevelam can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Dexamethasone can be increased when it is combined with Conivaptan.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin can be decreased when used in combination with Dexamethasone.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.
DabrafenibThe serum concentration of Dexamethasone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Dexamethasone.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Dexamethasone.
DeferasiroxThe serum concentration of Dexamethasone can be decreased when it is combined with Deferasirox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Dexamethasone.
DesmopressinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Desmopressin.
DihydrotestosteroneDexamethasone may increase the fluid retaining activities of Dihydrotestosterone.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Dexamethasone.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Dexamethasone.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Dexamethasone.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Dexamethasone.
FluconazoleThe metabolism of Dexamethasone can be decreased when combined with Fluconazole.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Dexamethasone.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Dexamethasone.
FosaprepitantThe serum concentration of Dexamethasone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Dexamethasone can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Dexamethasone can be increased when it is combined with Fusidic Acid.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Dexamethasone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Dexamethasone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dexamethasone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Dexamethasone.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Dexamethasone.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Dexamethasone.
IcosapentThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Icosapent.
IdelalisibThe serum concentration of Dexamethasone can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dexamethasone resulting in a loss in efficacy.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Dexamethasone.
IndacaterolIndacaterol may increase the hypokalemic activities of Dexamethasone.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Dexamethasone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Dexamethasone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dexamethasone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Dexamethasone.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Dexamethasone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dexamethasone.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Dexamethasone.
IvacaftorThe serum concentration of Dexamethasone can be increased when it is combined with Ivacaftor.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Dexamethasone.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Dexamethasone.
LeflunomideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Leflunomide.
LenalidomideDexamethasone may increase the thrombogenic activities of Lenalidomide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Dexamethasone.
LuliconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Luliconazole.
Magnesium oxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.
MifepristoneThe therapeutic efficacy of Dexamethasone can be decreased when used in combination with Mifepristone.
MitotaneThe serum concentration of Dexamethasone can be decreased when it is combined with Mitotane.
NatalizumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.
NelfinavirThe metabolism of Dexamethasone can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Dexamethasone can be increased when it is combined with Netupitant.
NicorandilThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nicorandil.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Dexamethasone.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Dexamethasone.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Dexamethasone.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Dexamethasone.
OxandroloneDexamethasone may increase the fluid retaining activities of Oxandrolone.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Dexamethasone.
PalonosetronThe serum concentration of Dexamethasone can be increased when it is combined with Palonosetron.
PhenobarbitalThe serum concentration of Dexamethasone can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Dexamethasone can be decreased when it is combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone.
PrimidoneThe serum concentration of Dexamethasone can be decreased when it is combined with Primidone.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Dexamethasone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Dexamethasone.
RifabutinThe serum concentration of Dexamethasone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Dexamethasone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Dexamethasone can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Dexamethasone.
RoflumilastRoflumilast may increase the immunosuppressive activities of Dexamethasone.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Dexamethasone.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Dexamethasone.
SaquinavirThe serum concentration of Dexamethasone can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Dexamethasone.
SiltuximabThe serum concentration of Dexamethasone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Dexamethasone.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexamethasone.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Dexamethasone.
SparfloxacinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Sparfloxacin.
St. John's WortThe serum concentration of Dexamethasone can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Dexamethasone can be increased when it is combined with Stiripentol.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Dexamethasone.
TacrineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Dexamethasone.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Dexamethasone.
TesmilifeneThe serum concentration of Dexamethasone can be decreased when it is combined with Tesmilifene.
TestosteroneDexamethasone may increase the fluid retaining activities of Testosterone.
ThalidomideDexamethasone may increase the dermatologic adverse activities of Thalidomide.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Dexamethasone resulting in a loss in efficacy.
TocilizumabThe serum concentration of Dexamethasone can be decreased when it is combined with Tocilizumab.
TofacitinibDexamethasone may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dexamethasone.
TorasemideDexamethasone may increase the hypokalemic activities of Torasemide.
TrastuzumabTrastuzumab may increase the neutropenic activities of Dexamethasone.
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Dexamethasone.
TrichlormethiazideDexamethasone may increase the hypokalemic activities of Trichlormethiazide.
VerapamilThe serum concentration of Dexamethasone can be increased when it is combined with Verapamil.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dexamethasone.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Dexamethasone.
WarfarinDexamethasone may increase the anticoagulant activities of Warfarin.
Food Interactions
  • Avoid alcohol.
  • Avoid taking with grapefruit juice.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Warne JP, John CD, Christian HC, Morris JF, Flower RJ, Sugden D, Solito E, Gillies GE, Buckingham JC: Gene deletion reveals roles for annexin A1 in the regulation of lipolysis and IL-6 release in epididymal adipose tissue. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1264-73. Epub 2006 Jul 11. [PubMed:16835395 ]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  3. Funato H, Kobayashi A, Watanabe Y: Differential effects of antidepressants on dexamethasone-induced nuclear translocation and expression of glucocorticoid receptor. Brain Res. 2006 Oct 30;1117(1):125-34. Epub 2006 Sep 7. [PubMed:16956592 ]
  4. Vaitkuviene A, Ulinskaite A, Meskys R, Duburs G, Klusa V, Liutkevicius E: Study of the interaction of 1,4-dihydropyridine derivatives with glucocorticoid hormone receptors from the rat liver. Pharmacol Rep. 2006 Jul-Aug;58(4):551-8. [PubMed:16963802 ]
  5. Wang D, Zhang H, Lang F, Yun CC: Acute activation of NHE3 by dexamethasone correlates with activation of SGK1 and requires a functional glucocorticoid receptor. Am J Physiol Cell Physiol. 2007 Jan;292(1):C396-404. Epub 2006 Sep 13. [PubMed:16971495 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
stimulator
General Function:
Transcription factor binding
Specific Function:
Orphan nuclear receptor. Component of a cascade required for the development of the hypothalamic-pituitary-adrenal-gonadal axis. Acts as a coregulatory protein that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions. May also have a role in the development of the embryo and in the maintenance of embryonic stem cell pluripotency (By similarity).
Gene Name:
NR0B1
Uniprot ID:
P51843
Molecular Weight:
51717.185 Da
References
  1. Gummow BM, Scheys JO, Cancelli VR, Hammer GD: Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Mol Endocrinol. 2006 Nov;20(11):2711-23. Epub 2006 Jul 20. [PubMed:16857744 ]
  2. Yu CC, Li PH: In vivo inhibition of steroidogenic acute regulatory protein expression by dexamethasone parallels induction of the negative transcription factor DAX-1. Endocrine. 2006 Dec;30(3):313-23. [PubMed:17526944 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Structural molecule activity
Specific Function:
Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Promotes resolution of inflammation and wound healing (PubMed:25664854). Functions ...
Gene Name:
ANXA1
Uniprot ID:
P04083
Molecular Weight:
38713.855 Da
References
  1. Morand EF, Hall P, Hutchinson P, Yang YH: Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediators Inflamm. 2006;2006(2):73835. [PubMed:16883066 ]
  2. John CD, Theogaraj E, Christian HC, Morris JF, Smith SF, Buckingham JC: Time-specific effects of perinatal glucocorticoid treatment on anterior pituitary morphology, annexin 1 expression and adrenocorticotrophic hormone secretion in the adult female rat. J Neuroendocrinol. 2006 Dec;18(12):949-59. [PubMed:17076770 ]
  3. Davies E, Omer S, Buckingham JC, Morris JF, Christian HC: Expression and externalization of annexin 1 in the adrenal gland: structure and function of the adrenal gland in annexin 1-null mutant mice. Endocrinology. 2007 Mar;148(3):1030-8. Epub 2006 Dec 7. [PubMed:17158208 ]
  4. Wang C, Wang J, Guo HF, Liu RY: Involvement of annexin I in the dexamethasone-mediated upregulation of A549 cells phagocytosis of apoptotic eosinophils. Immunol Lett. 2007 Aug 15;111(2):103-10. Epub 2007 Jul 2. [PubMed:17644190 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Tetrahydrobiopterin binding
Specific Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-n...
Gene Name:
NOS2
Uniprot ID:
P35228
Molecular Weight:
131116.3 Da
References
  1. Soderberg M, Raffalli-Mathieu F, Lang MA: Regulation of the murine inducible nitric oxide synthase gene by dexamethasone involves a heterogeneous nuclear ribonucleoprotein I (hnRNPI) dependent pathway. Mol Immunol. 2007 May;44(12):3204-10. Epub 2007 Mar 26. [PubMed:17379310 ]
  2. Huang H, Lavoie-Lamoureux A, Moran K, Lavoie JP: IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1147-54. [PubMed:17494951 ]
  3. Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15. [PubMed:17503181 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 17-alpha-monooxygenase activity
Specific Function:
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
Gene Name:
CYP17A1
Uniprot ID:
P05093
Molecular Weight:
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V: Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology. 2001 Oct 5;167(1):37-46. [PubMed:11557128 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  3. Schuetz JD, Silverman JA, Thottassery JV, Furuya KN, Schuetz EG: Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids. Cell Growth Differ. 1995 Oct;6(10):1321-32. [PubMed:8845310 ]
  4. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  5. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  7. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
  8. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698-705. [PubMed:7560060 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R: Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett. 1999 Jan 15;442(2-3):208-14. [PubMed:9929003 ]
  2. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, Paumgartner G: Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett. 1998 Mar 13;424(3):173-6. [PubMed:9539145 ]
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Elahian F, Kalalinia F, Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 2010 Apr;33(2):113-9. doi: 10.3109/01480540903390000. [PubMed:20307139 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 01, 2016 02:26